文献速递浆细胞疾病

蛋白精氨酸甲基转移酶5在多发性骨髓瘤中具有预后意义并可作为可成药靶点

Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.
PubMed 文献 · Leukemia · 2017-11-21

研究鉴定并验证蛋白精氨酸甲基转移酶5(PRMT5)为多发性骨髓瘤(MM)的新治疗靶点。PRMT5在患者MM细胞中过表达并与无进展生存和总生存降低相关。遗传敲低或EPZ015666药理学抑制PRMT5可显著抑制细胞系和患者MM细胞生长,抑制NF-κB信号,并鉴定TRIM21为PRMT5新伴侣。口服EPZ015666在人源化小鼠模型中显著减少MM生长。

要点

  • PRMT5在MM患者细胞中过表达,且与无进展生存和总生存降低相关。
  • 遗传敲低或EPZ015666抑制PRMT5可显著抑制MM细胞系和患者MM细胞生长。
  • PRMT5抑制通过TRIM21依赖机制抑制NF-κB信号;口服EPZ015666在人源化小鼠模型中显著减少MM生长。

核心结论

  • PRMT5在MM发病机制中具有致癌作用和预后相关性,为靶向PRMT5改善患者结局的新疗法提供了依据。

研究设计与样本

  • 研究鉴定并验证PRMT5为MM新治疗靶点,采用遗传敲低和药理学抑制(EPZ015666)及人源化小鼠模型。

主要发现

  • PRMT5在患者MM细胞中过表达,并与无进展生存和总生存降低相关。
  • 遗传敲低或EPZ015666药理学抑制PRMT5显著抑制细胞系和患者MM细胞生长。
  • PRMT5抑制消除NF-κB信号;质谱鉴定TRIM21为新PRMT5伴侣,并阐明TRIM21依赖的NF-κB抑制机制。
  • 口服EPZ015666在人源化小鼠模型中显著减少MM生长。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Arginine methyltransferases critically regulate cellular homeostasis by modulating the functional outcome of their substrates. The protein arginine methyltransferase 5 (PRMT5) is an enzyme involved in growth and survival pathways promoting tumorigenesis. However, little is known about the biologic function of PRMT5 and its therapeutic potential in multiple myeloma (MM). In the present study, we identified and validated PRMT5 as a new therapeutic target in MM. PRMT5 is overexpressed in patient MM cells and associated with decreased progression-free survival and overall survival. Either genetic knockdown or pharmacological inhibition of PRMT5 with the inhibitor EPZ015666 significantly inhibited growth of both cell lines and patient MM cells. Furthermore, PRMT5 inhibition abrogated NF-κB signaling. Interestingly, mass spectrometry identified a tripartite motif-containing protein 21 TRIM21 as a new PRMT5-partner, and we delineated a TRIM21-dependent mechanism of NF-κB inhibition. Importantly, oral administration of EPZ015666 significantly decreased MM growth in a humanized murine model of MM. These data both demonstrate the oncogenic role and prognostic relevance of PRMT5 in MM pathogenesis, and provide the rationale for novel therapies targeting PRMT5 to improve patient outcome.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Gullà A, Hideshima T, Bianchi G, et al. Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia. 2017. PMID: 29158558. doi:10.1038/leu.2017.334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。